Table 4.
Adverse event/complaint | Diagnosis | Patients, n | Patients, % | Termination, n | Termination, % |
---|---|---|---|---|---|
Lack of IOP-lowering efficacy | POAG | 4 | 0.7 | 3 | 0.5 |
OH | 1 | 0.2 | 0 | 0.0 | |
PEX | 2 | 0.3 | 0 | 0.0 | |
NTG | 1 | 0.2 | 1 | 0.2 | |
Other glaucomas | 1 | 0.2 | 0 | 0.0 | |
Conjunctival hyperemia | OH | 2 | 0.3 | 1 | 0.2 |
POAG | 1 | 0.2 | 0 | 0.0 | |
Hyperemia and eyelid hyperpigmentation | OH | 1 | 0.2 | 1 | 0.2 |
Itching | POAG | 1 | 0.2 | 1 | 0.2 |
Headache | POAG | 1 | 0.2 | 1 | 0.2 |
Increased contrast sensitivity | POAG | 1 | 0.2 | 1 | 0.2 |
Patient decision | NTG | 2 | 0.3 | 2 | 0.3 |
Unknown | POAG | 1 | 0.2 | 1 | 0.2 |
Total | 19 | 3.3 | 12 | 2.1 | |
Remaining on monotherapy after final visit (month 3) | 567 | 97.9 | |||
Total | 579 | 100.0 |
Abbreviations: NTG, normal tension glaucoma; OH, ocular hypertension; PEX, exfoliative glaucoma; POAG, primary open-angle glaucoma.